Fabino Enterprises Ltd
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | — | vs a year ago | 6M FY26 |
|---|---|---|---|
| Revenue from operations | — | — | 14.21 |
| Other income | — | — | 1.29 |
| Total income | — | — | 15.50 |
| Employee benefit expense | — | — | 0.03 |
| Finance costs | — | — | 0.04 |
| Depreciation & amortisation | — | — | 0.05 |
| Total expenses | — | — | 16.05 |
| Profit before tax | — | — | -0.55 |
| Tax expense | — | — | -0.18 |
| Profit after tax | — | — | -0.37 |
| Total comprehensive income | — | — | — |
| Earnings per share, basic | — | ₹-1.78 |
|---|---|---|
| Earnings per share, diluted | — | ₹-1.78 |
6M FY26 — from the company’s filing with BSE. Source
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
Fabino Enterprises Ltd has not filed a concall transcript in the last 4 quarters.
Filings
12 shown · 29 published by the exchange
12 Oct 2026
01 Oct 2026
29 Sept 2026
Filing29 Sept 2026
29 Sept 2026
25 Sept 2026
Insider trading06 Sept 2026
Filing04 Sept 2026
04 Sept 2026
04 Sept 2026
04 Sept 2026
Filing04 Sept 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 12 Oct 2026.